Table 3. . Summary of analysis of CYP2D6 activity scores, CYP2D6 metabolizer phenotype and CYP2D6 extreme metabolizer phenotype with tardive dyskinesia occurrence and tardive dyskinesia severity (log Abnormal Involuntary Movement Scale scores).

TD occurrence	CAUS sample		PGx sample
	OR (95% CI)	p-value	OR (95% CI)	p-value
Activity score†	0.987 (0.604–1.612)	0.957	0.361 (0.139–0.938)	0.037‡
Metabolizer phenotype†	0.863 (0.459–1.621)	0.647	0.343 (0.119–0.989)	0.048‡
Extreme metabolizer phenotype	5.580 (1.454–21.410)	0.012‡	8.066 (0.646–100.748)	0.105
AIMS scores	Beta (95% CI)	p-value	Beta (95% CI)	p-value
Activity score†	0.014 (-0.096–0.124)	0.804	-0.13 (-0.282–0.016)	0.079
Metabolizer phenotype†	-0.024 (-0.165–0.118)	0.741	-1.43 (-0.309–0.023)	0.089
Extreme metabolizer phenotype	0.277 (0.025–0.530)	0.032‡	0.292 (-0.090–0.674)	0.131

^†CYP2D6 activity scores and CYP2D6 metabolizer phenotypes were defined according to the Clinical Pharmacogenetics Implementation Consortium system.

^‡p-values less than 0.05.

AIMS: Abnormal Involuntary Movement Scale; OR: Oodds ratio; PGx: Pharmacogenomic; TD: Tardive dyskinesia.